Phage therapy for chronic achromobacter lung infection in cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests whether giving you a mixture of viruses (called phages) that specifically target the bacteria Achromobacter can help treat your chronic lung infection. You would breathe in the phages, and the study will check if this is safe and helps improve your breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cystic fibrosis (CF), even if you've had a lung transplant.
- You have a chronic Achromobacter infection, meaning it's been found in your sputum or throat swabs at least twice in the last 2 years, and at least once in the last year.
- Your lung function (FEV1) is at least 40% of what's expected for someone your age.
- Your breathing symptoms have been stable for the past 30 days, and you haven't changed your CF medications in that time.
- You are willing to travel to Pittsburgh or San Diego for the study visits if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
This study tests whether using air cleaners in your home can improve lung health for people with cystic fibrosis (CF) or primary ciliary dyskinesia (PCD). It takes place in Cyprus and requires you to stay at home most days.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests a treatment that uses special viruses (called phages) to kill antibiotic-resistant bacteria causing pneumonia in people on ventilators. If you're eligible, this new approach might help fight the infection when standard antibiotics aren't working well.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.